Breaking News

Catalent Issues Letter Regarding Pending Acquisition by Novo Holdings

Alessandro Maselli will continue to lead Catalent as President and CEO following the transaction close.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent has issued an open letter to customers regarding the pending acquisition by Novo Holdings.   In the letter, President and Chief Executive Officer of Catalent, Alessandro Maselli, states, “I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings’ pending acquisition of Catalent and reiterate that we are, and will continue to be, driven by our mission to develop, manufacture and supply products.”   Following the closing of the transaction, ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters